HCPCS code J0588: IncobotulinumtoxinA, per 1 unit2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J0588 covers

IncobotulinumtoxinA, marketed as Xeomin, is a botulinum toxin used to reduce excessive muscle activity or salivary secretion. Neurologists, physiatrists, ophthalmologists, and other clinicians may administer it by injection for conditions such as cervical dystonia, spasticity, blepharospasm, or chronic sialorrhea. The treatment site and injection approach depend on the condition being treated.

J0588 identifies the drug, not the injection service. One HCPCS unit represents one unit of incobotulinumtoxinA; report the quantity administered in those units, not in milliliters or vials. Its physician fee schedule status is E, so CMS excludes it from the physician fee schedule. When Medicare covers the drug, payment is under another method; HCPCS classifies it as a Part B drug, generally priced using CMS quarterly Average Sales Price drug pricing files. The Medicare contractor determines coverage.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J0588 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J0588 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J0588 rate is calculated

Each of J0588’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J0588

J0588 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J0588 compared with similar codes

How to choose

J0585OnabotulinumtoxinAPer 1 unit

J0585 reports onabotulinumtoxinA, while J0588 reports incobotulinumtoxinA. Select the code for the product administered; do not treat their units as interchangeable.

J0586AbobotulinumtoxinAPer 5 units

J0586 is for abobotulinumtoxinA, not incobotulinumtoxinA. The product administered determines which drug code applies.

J0587RimabotulinumtoxinBPer 100 units

J0587 identifies rimabotulinumtoxinB. J0588 identifies incobotulinumtoxinA, a different drug product.

J0589DaxibotulinumtoxinAPer 1 unit

J0589 identifies daxibotulinumtoxinA-lanm, whereas J0588 identifies incobotulinumtoxinA. Report the code matching the administered product.

Codes related to J0588

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates